VNRX צמיחת רווח למניה בשנה הנוכחית volition.com
VolitionRx Limited leads in epigenetic oncology screening by investing in the unique Nucleosomics technology. Year-over-year changes in EPS reflect capital dynamics, where the value of 55.70 expresses the metric level. AI-powered robotic systems accelerate blood analysis, providing the company with a competitive advantage due to the platform's versatility in both human and veterinary medicine.
פילוחים אנליטיים ודוחות נתונים של חברת volition.com (VNRX)
Investors use this indicator as a leading signal for future stock returns. The metric captures the percentage deviation of current earnings per share from the same value last year. Current annual EPS progress has reached 55.70. This price action reflects the monetization efficiency of the Nu.Q platform. The strong pricing power of VolitionRx Limited (VNRX) in the early cancer diagnostics segment converts directly into the growth of this fundamental indicator.
